Emergent BioSolutions Inc.
EBSEmergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Drugs in Pipeline
11
Phase 3 Programs
4
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
EBS Earnings Report
FQ end 2026-06 | Call: 2026-08-05 15:00:00
How EBS's past catalysts played out
HuMax-CD4
T Cell Lymphoma
AV7909
Anthrax
ACAM2000
Smallpox Vaccine Adverse Reaction
BioThrax
Anthrax
ACAM2000 Smallpox Vaccine
Smallpox
AIGIV 3.5 mg/kg
Anthrax
Ciprofloxacin 500Mg Tablet
Anthrax
Vaccinia virus: ACAM2000 smallpox vaccine
Smallpox
Dose of 5.0 x 10^9 CFU (Cohort 1)
Typhoid
Ciprofloxacin
Anthrax
FLU-IGIV
Influenza A H3N2
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HuMax-CD4 | Phase 3 | T Cell Lymphoma | - | - |
AV7909 | Phase 3 | Anthrax | - | - |
ACAM2000 | Phase 3 | Smallpox Vaccine Adverse Reaction | - | - |
BioThrax | Phase 3 | Anthrax | - | - |
ACAM2000 Smallpox Vaccine | Phase 2 | Smallpox | - | - |
AIGIV 3.5 mg/kg | Phase 2 | Anthrax | - | - |
Ciprofloxacin 500Mg Tablet | Phase 2 | Anthrax | - | - |
Vaccinia virus: ACAM2000 smallpox vaccine | Phase 2 | Smallpox | - | - |
Dose of 5.0 x 10^9 CFU (Cohort 1) | Phase 2 | Typhoid | - | - |
Ciprofloxacin | Phase 2 | Anthrax | - | - |
FLU-IGIV | Phase 2 | Influenza A H3N2 | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Emergent BioSolutions Inc.'s drug pipeline?→
CatalystAlert tracks 11 drug candidates in Emergent BioSolutions Inc.'s (EBS) pipeline across Phase 3, Phase 2. Its lead program is HuMax-CD4 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Emergent BioSolutions Inc.'s next FDA catalyst?→
Emergent BioSolutions Inc.'s (EBS) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track EBS biotech catalysts?→
Add EBS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Emergent BioSolutions Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.